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Figure 1. Stones from the urinary tract
Figure 2. Intravenous pielography examination: plain (left) and 
post-voiding (right) show bilateral staghorn stones
Figure 3. Parathyroid scan (99mTc-MIBI, 15 mCi) show 
over-radioactivity (uptake) of lower right parathyroid gland
Figure 4. Parathyroid SPECT/CT show adenoma of the lower right parathyroid gland
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Primary hyperparathyroidism is a medical 
condition caused by overactive of parathyroid 
gland.1 It is most commonly caused by solitary 
adenoma of the parathyroid gland.1,2 Other 
causes of this condition are hyperplasia, multiple 
adenomas, and parathyroid cancer.1 Primary 
hyperparathyroidism has some metabolic 
consequences in the calcium metabolism.1-3 
Hypercalcemia in patient with primary 
hyperparathyroidism will resulted to the most 
important comorbidity that is chronic deposition 
of calcium in the kidney forming nephrolithiasis 
or other urolithiasis.3 It is not uncommon, patient 
with parathyroid adenoma come to health 
care professionals with the chief complain of 
recurrence nephrolithiasis.1,4 
Nephrolithiasis develop from metabolic 
abnormalities or anatomic malformations of 
the urinary tract and infection.4 Around 10-20% 
of nephrolithiasis cases are form in staghorn 
type. According to Amaro CRP et al.4, staghorn 
calculus is the most severe presentation of 
urinary tract lithiasis, therefore they need further 
metabolic investigations in the case of staghorn 
stones. Study reported that hypercalciuria are the 
most common characteristics in staghorn calculus 
and investigation for hypercalcemia need to be 
explored.3,4 Unfortunately, study reported the 
under-investigation and underestimation of 
further metabolic investigation for staghorn 
calculus. Shortly, further metabolic investigation 
is important to prevent the recurrency of staghorn 
calculus.4
P r imary  hyperpara thyro id i sm and 
malignancy are responsible for more than 90% of 
all cases of hypercalcemia.5 Assadi F stated that 
hyperparathyroidism is associated with lower 
serum calcium levels (<12 mg/dL) and longer 
duration of hypercalcemia (more than 6 months) 
compared to malignancy. Parathyroid hormone 
assay is the most useful test for differentiating 
hyperparathyroidism from malignancy and other 
causes of hypercalcemia.5 While adenoma of 
parathyroid gland is suspected, examination 
with 99mTc-MIBI SPECT/CT is the next step 
for diagnostic purpose.6
This is a classic and good case to learn 
about recurrent staghorn calculus/stones, 
hypercalcemia, hyperparathyroidism, and 
adenoma of the parathyroid gland. A 28 year-
old female came with the complaint of recurrent 
bilateral retroperitoneal pain. She was also 
complaining of stones excretion in the urine 
(Figure 1). From intravenous pielography 
examination, there was a bilateral staghorn 
calculus in both (right and left) kidneys (Figure 
2). She had a history of recurrent staghorn stones 
in the past five years. She had experienced 
surgery, three times ESWL (extracorporeal shock 
wave lithotripsy), and PCNL (percutaneous 
nephro-lithotripsy) by urologic surgeon, but the 
bilateral stones always recur in the evaluation.
From the physical examination, the patient 
was obese, with costovertebral angle tenderness 
in the right and left (bilateral) sides, and positive 
ballotement test. Other organs revealed in the 
normal condition from physical examination. 
From laboratory examination, there was 
hypercalcemia with calcium serum 12.3 mg/dL 
(normal range 8.4 to 102 mg/dL). For further 
metabolic investigation for hypercalcemia, we 
perform test of parathyroid hormone assay and 
we get hyperparathyroidism with parathyroid 
hormone 344.3 pg/mL (normal range 15-65 pg/
mL). Other laboratory examinations (peripheral 
blood, kidney, and liver function) in the normal 
range.
From the neck ultrasound (cervical 
ultrasonography), we found no abnormalities and 
the investigation was continued with parathyroid 
scintigraphy with 99mTc-MIBI scan by SPECT/
CT. From parathyroid scan, the patient has 
adenoma in the lower right parathyroid gland. 
The patient was consulted to oncologic surgeon 
to undergo parathyroidectomy. Ten days after 
surgery, parathyroid hormone was decreased 
from 344.3 pg/mL to 106.9 pg/mL (normal 
range 15-65 pg/mL) and serum calcium was 
decreased to 10.2 mg/dL. From histopathology 
examination the adenoma was classified as 
benign (hyperplastic of the parathyroid gland). 
Post-parathyroidectomy, the patient was planned 
to undergo surgery, ESWL, and PCNL for the 
rest of the recent staghorn stones.
Primary hyperparathyroidism is a common 
metabolic disorders that affect calcium 
metabolism resulting hypercalcemia.1,2,7 It has 
female preponderance.7 The patient usually come 
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to health care fasilities with nephrolithiasis or 
urolithiasis and bone disease (osteoporosis).1,7 In 
many cases, hyperparathyroidism can be found 
incidentally from screening of calcium serum.7  
Primary hyperparathyroidism differ from 
secondary hyperparathyroidism.1 Chronic 
kidney disease is the most common cause of 
secondary hyperparathyroidism which the 
hypocalcemia occur first following the deficiency 
of 25-hydroxy-vitamin D and 1.25 dihydroxy-
vitamin D, inducing hyperactivity of parathyroid 
glands. Secondary hyperparathyroidism then 
increase the reabsorption of calcium ion and 
calcitriol synthesis. High turn over of the bone 
will resulted to decrease of bone mineral density 
and increase the risk of pathologic fractures.8 
It is noted to always check kidney function 
test to exclude secondary hyperparathyroidism 
from chronic kidney disease.1 Other causes of 
secondary hyperparathyroidism must be excluded 
which are the use of thiazide diuretics and lithium, 
vitamin D deficiency, bisphosphonates, and also 
genetic cause such as familial hypocalciuric 
hypercalcemia.1
There are only few guidelines on the 
management of primary hyperparathyroidism. 
A scientific statement from Brazilian Society 
for Endocrinology and Metabolism suggested 
the examination of serum calcium, parathyroid 
hormone assay, vitamin D, and serum creatinine, 
renal ultrasound, and bone mineral densitometry 
of the lumbar spine, femur, and distal 1/3 
radius by dual energy X-ray absorptiometry 
(DXA) for work up of hyperparathyroidism.1 
From a survey of 421 physicians in Europe 
consisting of endocrinologists, rheumatologists, 
internists, and urologists who managed primary 
hyperparathyroidism, majority will check 
parathyroid hormone, serum calcium, serum 
creatinine, and 24-hours urinary excretion of 
calcium for diagnostic tests used for patients 
suspected to primary hyperparathyroidism.7
Imaging procedure options to find the 
abnormalities in the parathyroid glands are 
cervical ultrasonography (neck ultrasound), 
computed tomography, magnetic resonance 
imaging, 99mTc-MIBI (sestamibi) scintigraphy, 
and PTH measurement in nodule aspiration 
fluid (fine needle aspiration).1 In recent years, 
99mTc-MIBI (sestamibi) single-photon emission 
computed tomography and computed tomography 
scintigraphy (SPECT/CT) have routinely used 
to detect adenoma and malignancy (cancer) of 
the parathyroid glands.6 Our patient underwent 
99mTc-MIBI (sestamibi) scintigraphy by 
SPECT/CT after she highly suspected as having 
primary hyperparathyroidism from laboratory 
examination. From the scintigraphy and SPECT/
CT, she are known to have single adenoma of 
parathyroid gland  with the location in the lower 
right gland. In the Figure 3 and Figure 4 we can 
see high uptake of the radioactive 99m Tecnetium 
in one of the four parathyroid glands.
Parathyroidectomy is the treatment of 
choice for patients with symptomatic primary 
hyperparathyroidectomy.1,2 Several indications 
for  surgery in  asymptomatic  pr imary 
hyperparathyroidism are serum calcium >1 
mg/dL above upper limit of normal, creatinine 
clearance <60 mL/min/1.73 m2, T-score <2,5 
at the lumbar spine, hip, and/or distal radius 
or previous fragility fracture, age <50 years, 
and patients whose medical monitoring is not 
possible.1 Our patient has recurrence bilateral 
staghorn stones which classify her as having 
symptomatic primary hyperparathyroidectomy. 
The benefit of parathyroidectomy are summarized 
by the Brazilian Society for Endocrinology and 
Metabolism statement, which are improved 
bone mineral density result, decreased risk of 
fractures, reduced risk of nephrolithiasis, and 
improved quality of life.1 Our patient underwent 
parathyroidectomy of the lower right gland. 
After surgery, parathyroid hormone decreased 
dramatically from 344.3 pg/mL to 106.9 pg/
mL (normal range 15-65 pg/mL), followed by 
decreased of the serum calsium to 10.2 mg/dL. 
It will also decreased the risk of future stones 
formation in the kidney and urinary tract.
Monitoring of parathyroid hormone, serum 
calcium, and clinical symptoms of the staghorn 
stones are mandatory for all patients after 
parathyroidectomy. Phamacological treatment 
can be indicated for patients with contraindications 
for surgery, surgical failure, and those with no 
current indication for surgery.1 Several drugs 
for primary hyperparathyroidism are cinacalnet 
hydrochloride which is calcimimetic agent that 
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binds to calcium-sensing receptor of parathyroid 
cells and decresed PTH secretion, selective 
modulators of estrogen receptors (SERM) 
such as raloxifene, and biphosphonates such as 
alendronate.1
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